Intravenous AAV9 Gene Therapy for MPS IIIA and MPS IIIB

Cure Sanfilippo Foundation awarded a grant to Abeona Therapeutics, a privately-traded company that is managing license & toxicology/drug production for the AAV9 gene therapy clinical trial at Nationwide Children’s Hospital. 

Project Summary: Support of formal GMP toxicology study in preparation for human clinical trial; Support for Gene therapy Drug Production to be used in human clinical trial.

Start date: October 2014

March 2017: MPSIIIA trial was initiated in May 2016. IND has been approved for commencement of MPSIIIB gene therapy trial.

Cure Sanfilippo Foundation

501c3 non-profit
(Tax ID: 46-4322131)

curesff@gmail.com

P.O. Box 6901
Columbia, SC 29260

N